Common use of Parties Obligations Clause in Contracts

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATION, which will be provided by the latter, and also the indications on the performance of the TRIALS given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALS, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALS, and those for analysing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATION’s obligation is the financial management of these TRIALS, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALS, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulations.

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS STUDY made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATIONFIBHULP, which will be provided by the latter, and also the indications on the performance of the TRIALS STUDY given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALSSTUDY, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALSSTUDY, and those for analysing analyzing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATIONFIBHULP’s obligation is the financial management of these TRIALSSTUDY, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule APPENDIX I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS STUDY for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALSSTUDY, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule APPENDIX II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulationsregulations FIVE.- FINANCIAL ASPECTS The cost of these STUDY has been initially budgeted at ……………. EUROS, not including VAT, (€……………….) (hereinafter, the STUDY BUDGET). This amount has been determined by applying the cost of…………………….……..EUROS (€………………………) per evaluable patient, in accordance with the provisions of the Financial Memorandum for the STUDY (APPENDIX I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FIBHULP, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products Furthermore, on signature of this contract, the SPONSOR will pay the amount of 1.000 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs The amount to be paid by the SPONSOR/CRO during performance of the STUDY will be calculated by applying APPENDIX I and must be paid to the FIBHULP in the payments set out below: The STUDY budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in APPENDIX I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FIBHULP every six (6) months These payments are considered to be payments on account, pending payment of the definitive total for the STUDY The definitive total to be paid by the SPONSOR/CRO for performing the STUDY will be calculated based on the work effectively carried out to perform the STUDY (hereinafter, the DEFINITIVE TOTAL). The DEFINITIVE TOTAL will be calculated as follows: Within a maximum of three (3) months after termination of the STUDY at the HOSPITAL, the SPONSOR/CRO and the LEAD INVESTIGATOR will notify the FIBHULP in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (APPENDIX I). As soon as possible after the information referred to in the previous paragraph has been notified, the FIBHULP will calculate, issue and notify the SPONSOR/CRO in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR, or FINANCIAL MANAGER designated: INVOICES WILL BE ISSUED TO NAME CIF/VAT NUMBER/ ID ADDRESS INVOICES WILL BE SENDED TO NAME ADDRESS INVOICES WILL BE PAYED FOR (*) In order for FIBHULP to issue the invoices corresponding to the costs detailed in the budget (ANNEX_1), the SPONSOR/CRO must inform FIBHULP in writing of the total amount to be invoiced, detailing the breakdown of the visits and procedures that have been carried out. To do so, he/she shall send an e-mail to xxxxxxxxxxxxxxx@xxxxxx.xx (**) If it is necessary to include an order or purchase order number in the invoices, this must be indicated, along with the procedure for the FIBHULP to request it Payments to the FIBHULP will be made by bank transfer, with charges payable by the sender, to: HOLDER Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP) TAX ID CODE ESG83727057 BANK La Caixa Xx. xx xx Xxxxxxxxxxx Xxxxx xx Xxxxxxxxx, 00 28037 Madrid IBAN XX00 0000 0000 0000 0000 2143 SWIFT CAIXE SBB Payments made by the SPONSOR/CRO (choose as appropriate) to the FOUNDATION will be full settlements for the former, with the FIBHULP being responsible for payment the amounts that, as appropriate, are payable to the STUDY researchers.

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATION, which will be provided by the latter, and also the indications on the performance of the TRIALS given by the CEIm responsible for monitoring themit. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALS, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALS, and those for analysing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATION’s obligation is the financial management of these TRIALSthis TRIAL, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALS, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulations.

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS STUDY made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATIONFIBHULP, which will be provided by the latter, and also the indications on the performance of the TRIALS STUDY given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALSSTUDY, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALSSTUDY, and those for analysing analyzing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATIONFIBHULP’s obligation is the financial management of these TRIALSSTUDY, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule APPENDIX I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS STUDY for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALSSTUDY, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule APPENDIX II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulationsregulations FIVE.- FINANCIAL ASPECTS The cost of these STUDY has been initially budgeted at ……………. EUROS, not including VAT, (€……………….) (hereinafter, the STUDY BUDGET). This amount has been determined by applying the cost of…………………….……..EUROS (€………………………) per evaluable patient, in accordance with the provisions of the Financial Memorandum for the STUDY (APPENDIX I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FIBHULP, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products Furthermore, on signature of this contract, the SPONSOR will pay the amount of 2.000 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs The amount to be paid by the SPONSOR/CRO during performance of the STUDY will be calculated by applying APPENDIX I and must be paid to the FIBHULP in the payments set out below: The STUDY budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in APPENDIX I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FIBHULP every six (6) months These payments are considered to be payments on account, pending payment of the definitive total for the STUDY The definitive total to be paid by the SPONSOR/CRO for performing the STUDY will be calculated based on the work effectively carried out to perform the STUDY (hereinafter, the DEFINITIVE TOTAL). The DEFINITIVE TOTAL will be calculated as follows: Within a maximum of three (3) months after termination of the STUDY at the HOSPITAL, the SPONSOR/CRO and the LEAD INVESTIGATOR will notify the FIBHULP in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (APPENDIX I). As soon as possible after the information referred to in the previous paragraph has been notified, the FIBHULP will calculate, issue and notify the SPONSOR/CRO in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR, or FINANCIAL MANAGER designated: INVOICES WILL BE ISSUED TO NAME CIF/VAT NUMBER/ ID ADDRESS INVOICES WILL BE SENDED TO NAME ADDRESS

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS STUDY made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATIONFIBHULP, which will be provided by the latter, and also the indications on the performance of the TRIALS STUDY given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALSSTUDY, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALSSTUDY, and those for analysing analyzing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATIONFIBHULP’s obligation is the financial management of these TRIALSSTUDY, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule APPENDIX I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS STUDY for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALSSTUDY, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule APPENDIX II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulationsregulations FIVE.- FINANCIAL ASPECTS The cost of these STUDY has been initially budgeted at ……………. EUROS, not including VAT, (€……………….) (hereinafter, the STUDY BUDGET). This amount has been determined by applying the cost of…………………….……..EUROS (€………………………) per evaluable patient, in accordance with the provisions of the Financial Memorandum for the STUDY (APPENDIX I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FIBHULP, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products Furthermore, on signature of this contract, the SPONSOR will pay the amount of 1.500 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs The amount to be paid by the SPONSOR/CRO during performance of the STUDY will be calculated by applying APPENDIX I and must be paid to the FIBHULP in the payments set out below: The STUDY budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in APPENDIX I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FIBHULP every six (6) months These payments are considered to be payments on account, pending payment of the definitive total for the STUDY. The definitive total to be paid by the SPONSOR/CRO for performing the STUDY will be calculated based on the work effectively carried out to perform the STUDY (hereinafter, the DEFINITIVE TOTAL). The DEFINITIVE TOTAL will be calculated as follows: Within a maximum of three (3) months after termination of the STUDY at the HOSPITAL, the SPONSOR/CRO and the LEAD INVESTIGATOR will notify the FIBHULP in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (APPENDIX I). As soon as possible after the information referred to in the previous paragraph has been notified, the FIBHULP will calculate, issue and notify the SPONSOR/CRO in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR, or FINANCIAL MANAGER designated: INVOICES WILL BE ISSUED TO NAME CIF/VAT NUMBER/ ID ADDRESS INVOICES WILL BE SENDED TO NAME ADDRESS INVOICES WILL BE PAYED FOR (*) In order for FIBHULP to issue the invoices corresponding to the costs detailed in the budget (ANNEX_1), the SPONSOR/CRO must inform FIBHULP in writing of the total amount to be invoiced, detailing the breakdown of the visits and procedures that have been carried out. To do so, he/she shall send an e-mail to xxxxxxxxxxxxxxx@xxxxxx.xx (**) If it is necessary to include an order or purchase order number in the invoices, this must be indicated, along with the procedure for the FIBHULP to request it Payments to the FIBHULP will be made by bank transfer, with charges payable by the sender, to: HOLDER Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP) TAX ID CODE ESG83727057 BANK La Caixa Xx. xx xx Xxxxxxxxxxx Xxxxx xx Xxxxxxxxx, 00 28037 Madrid IBAN XX00 0000 0000 0000 0000 2143 SWIFT CAIXE SBB Payments made by the SPONSOR/CRO (choose as appropriate) to the FIBHULP will be full settlements for the former, with the FIBHULP being responsible for payment the amounts that, as appropriate, are payable to the STUDY researchers. (*) Include point 5.7 only if applicable The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the STUDY, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FIBHULP and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: …………………………………………………………….. …………………………………………………………….. The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the STUDY and, when they have ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FIBHULP When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the STUDY, the SPONSOR may assign the Equipment to the HOSPITAL, or the FIBHULP, free-of-charge, for which purpose such documents as are necessary will be formalized. In the event that additional needs for equipment are detected during performance of the STUDY, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS CLINICAL TRIAL made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATION, which will be provided by the latter, and also the indications on the performance of the TRIALS CLINICAL TRIAL given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALSCLINICAL TRIAL, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALSCLINICAL TRIAL, and those for analysing analyzing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATIONFIBHULP’s obligation is the financial management of these TRIALSCLINICAL TRIAL, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule APPENDIX I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS CLINICAL TRIAL for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALSCLINICAL TRIAL, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule APPENDIX II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulationsregulations FIVE. - FINANCIAL ASPECTS The cost of these CLINICAL TRIAL has been initially budgeted at ……………. EUROS, not including VAT, (€……………….) (hereinafter, the CLINICAL TRIAL BUDGET). This amount has been determined by applying the cost of…………………….……..EUROS (€………………………) per evaluable patient, in accordance with the provisions of the Financial Memorandum for the CLINICAL TRIAL (APPENDIX I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FIBHULP, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products Furthermore, on signature of this contract, the SPONSOR will pay the amount of 2.000 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs The amount to be paid by the SPONSOR/CRO during performance of the CLINICAL TRIAL will be calculated by applying APPENDIX I and must be paid to the FIBHULP in the payments set out below: The CLINICAL TRIAL budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in APPENDIX I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FIBHULP every six (6) months These payments are considered to be payments on account, pending payment of the definitive total for the CLINICAL TRIAL. The definitive total to be paid by the SPONSOR/CRO for performing the CLINICAL TRIAL will be calculated based on the work effectively carried out to perform the CLINICAL TRIAL (hereinafter, the DEFINITIVE TOTAL). The DEFINITIVE TOTAL will be calculated as follows: Within a maximum of three (3) months after termination of the CLINICAL TRIAL at the HOSPITAL, the SPONSOR/CRO and the LEAD INVESTIGATOR will notify the FIBHULP in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (APPENDIX I). As soon as possible after the information referred to in the previous paragraph has been notified, the FIBHULP will calculate, issue and notify the SPONSOR/CRO in a final invoice for the CLINICAL TRIAL, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR, or FINANCIAL MANAGER designated: INVOICES WILL BE ISSUED TO NAME CIF/VAT NUMBER/ ID ADDRESS INVOICES WILL BE SENDED TO NAME ADDRESS INVOICES WILL BE PAYED FOR NAME ADDRESS

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS CLINICAL TRIAL made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATION, which will be provided by the latter, and also the indications on the performance of the TRIALS CLINICAL TRIAL given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALSCLINICAL TRIAL, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALSCLINICAL TRIAL, and those for analysing analyzing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATIONFIBHULP’s obligation is the financial management of these TRIALSCLINICAL TRIAL, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule APPENDIX I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS CLINICAL TRIAL for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALSCLINICAL TRIAL, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule APPENDIX II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulationsregulations FIVE.- FINANCIAL ASPECTS The cost of these CLINICAL TRIAL has been initially budgeted at ……………. EUROS, not including VAT, (€……………….) (hereinafter, the CLINICAL TRIAL BUDGET). This amount has been determined by applying the cost of…………………….……..EUROS (€………………………) per evaluable patient, in accordance with the provisions of the Financial Memorandum for the CLINICAL TRIAL (APPENDIX I),which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FIBHULP, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products Furthermore, on signature of this contract, the SPONSOR will pay the amount of 2.000 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs The amount to be paid by the SPONSOR/CRO during performance of the CLINICAL TRIAL will be calculated by applying APPENDIX I and must be paid to the FIBHULP in the payments set out below: The CLINICAL TRIAL budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in APPENDIX I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FIBHULP every six (6) months These payments are considered to be payments on account, pending payment of the definitive total for the CLINICAL TRIAL The definitive total to be paid by the SPONSOR/CRO for performing the CLINICAL TRIAL will be calculated based on the work effectively carried out to perform the CLINICAL TRIAL be calculated as follows: Within a maximum of three (3) months after termination of the CLINICAL TRIAL at the HOSPITAL, the SPONSOR/CRO and the LEAD INVESTIGATOR will notify the FIBHULP in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (APPENDIX I). As soon as possible after the information referred to in the previous paragraph has been notified, the FIBHULP will calculate, issue and notify the SPONSOR/CRO in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR, or FINANCIAL MANAGER designated: INVOICES WILL BE ISSUED TO NAME CIF/VAT NUMBER/ ID ADDRESS INVOICES WILL BE SENDED TO NAME ADDRESS

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATION, which will be provided by the latter, and also the indications on the performance of the TRIALS given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALS, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALS, and those for analysing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATION’s obligation is the financial management of these TRIALS, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALS, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulations. FIVE. FINANCIAL ASPECTS The cost of these TRIALS has been initially budgeted at ___ EUROS, not including VAT, (€___) (hereinafter, the TRIALS Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FOUNDATION, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products. To request an invoice, contact: Furthermore, on signature of this contract, the SPONSOR will pay the amount of 1.500 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs. The amount to be paid by the SPONSOR/CRO (choose as appropriate) during performance of the TRIALS will be calculated by applying Schedule I and must be paid to the FOUNDATION in the payments set out below: The TRIALS budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in Schedule I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FOUNDATION every six months. These payments are considered to be payments on account, pending payment of the definitive total for the TRIALS. The definitive total to be paid by the SPONSOR/CRO (choose as appropriate) for performing the TRIALS will be calculated based on the work effectively carried out to perform the TRIALS (hereinafter, the Definitive Total). The Definitive Total will be calculated as follows: Within a maximum of three (3) months after termination of the TRIALS at the HOSPITAL, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will notify the FOUNDATION in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (Schedule I). As soon as possible after the information referred to in the previous paragraph has been notified, the FOUNDATION will calculate, issue and notify the SPONSOR/CRO (choose as appropriate), in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Name: VAT number / Tax ID Number Domicile / Registered Address Invoices will be sent for processing to the following e-mail: _____ The Sponsor/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to __________ Payments to the FOUNDATION will be made by bank transfer, with charges payable by the sender, to: Holder/Beneficiary: Fundación para la Investigación Biomédica del Hospital Universitario de Getafe. Bank: Banco Santander Address: Ctra. de Toledo, Km. 12,500, C.P. 28905, Getafe. Account Nº/IBAN: XX00 0000 0000 00 0000000000 VAT number /Tax ID CODE: ESG-83727024 Payments made by the SPONSOR/CRO (choose as appropriate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: _____ The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIALS and, when they have ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.

Parties Obligations. The PARTIES are under the obligation to perform the services provided for in this Contract in their entirety, in accordance with its content and that of the PROTOCOL. Furthermore, the PARTIES obligations include: Collaborating in visits monitoring the TRIALS CLINICAL TRIAL made by: (1) the CEIm, (2) monitors and auditors acting on instructions from the SPONSOR and (3) the relevant authorities, when they make inspections. These visits, apart from inspections, will be notified a minimum of one week in advance, unless a different time frame is agreed by the PARTIES. When such follow up, monitoring and audit visits are paid, such technical or organizational measures will be taken as ensure the maximum respect for the legislation on personal data protection. The LEAD INVESTIGATOR, the SPONSOR and the monitors and auditors will observe the internal procedural rules of the HOSPITAL and the FOUNDATION, which will be provided by the latter, and also the indications on the performance of the TRIALS CLINICAL TRIAL given by the CEIm responsible for monitoring them. The PARTIES may not agree, amongst themselves or with third parties unrelated to this document, in relation to the performance of the TRIALSCLINICAL TRIAL, agreements or terms unrelated to this one which obstruct, qualify, except, contravene or prevent performance of the respective obligations undertaken, or which involve undertaking others which are contrary to the applicable regulations. For this purpose, each one of the PARTIES declares that, at the date of this Contract, they are not a party to any agreement or pact which includes any of the agreements or terms referred to previously. In particular, under this Clause, the PARTIES accept that they may not agree or pay considerations of any kind other than those provided for in the Contract. The costs of the meetings held to organize and supervise performance of the TRIALSCLINICAL TRIAL, and those for analysing analyzing or publishing their results (presentations or scientific publications) are excluded from this prohibition. Apart from those provided for in the applicable regulations, the SPONSOR’s obligations are to give continuous support to the LEAD INVESTIGATOR and provide it and the CEIm with any new, relevant information which appears about the medication under investigation. The FOUNDATIONFIBHULP’s obligation is the financial management of these TRIALSCLINICAL TRIAL, receiving the payments made on account by the SPONSOR/CRO (choose whichever is appropriate) and distributing them in accordance with the provisions of Schedule APPENDIX I. The LEAD INVESTIGATOR undertakes to safeguard the identification codes of the subjects included. The SPONSOR, the LEAD INVESTIGATOR and the HOSPITAL, depending on their responsibilities, undertake to keep the essential documents for the TRIALS CLINICAL TRIAL for the time and under the conditions provided for in current legislation. The LEAD INVESTIGATOR is also responsible for selecting the members of the investigation team and support staff for the TRIALSCLINICAL TRIAL, which may be made up of natural persons and/or trading companies, or any other kind, who have the appropriate material and human resources to carry them out. Schedule APPENDIX II attached sets out a list of the members of the investigation team at the time this contract is signed. Any change to the investigation team must be notified to the CEIm in accordance with current regulationsregulations FIVE.- FINANCIAL ASPECTS The cost of these CLINICAL TRIAL has been initially budgeted at ……………. EUROS, not including VAT, (€……………….) (hereinafter, the CLINICAL TRIAL BUDGET). This amount has been determined by applying the cost of…………………….……..EUROS (€………………………) per evaluable patient, in accordance with the provisions of the Financial Memorandum for the CLINICAL TRIAL (APPENDIX I),which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FIBHULP, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products Furthermore, on signature of this contract, the SPONSOR will pay the amount of 2.000 Euros, in a one-off, non-refundable payment, by way of administrative and contractual management costs The amount to be paid by the SPONSOR/CRO during performance of the CLINICAL TRIAL will be calculated by applying APPENDIX I and must be paid to the FIBHULP in the payments set out below: The CLINICAL TRIAL budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in APPENDIX I, until the total amount of the Budget has been paid. For that purpose, the SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will report to the FIBHULP every six (6) months These payments are considered to be payments on account, pending payment of the definitive total for the CLINICAL TRIAL The definitive total to be paid by the SPONSOR/CRO for performing the CLINICAL TRIAL will be calculated based on the work effectively carried out to perform the CLINICAL TRIAL be calculated as follows: Within a maximum of three (3) months after termination of the CLINICAL TRIAL at the HOSPITAL, the SPONSOR/CRO and the LEAD INVESTIGATOR will notify the FIBHULP in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (APPENDIX I). As soon as possible after the information referred to in the previous paragraph has been notified, the FIBHULP will calculate, issue and notify the SPONSOR/CRO in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR, or FINANCIAL MANAGER designated: INVOICES WILL BE ISSUED TO NAME CIF/VAT NUMBER/ ID ADDRESS INVOICES WILL BE SENDED TO NAME ADDRESS INVOICES WILL BE PAYED FOR (*) In order for FIBHULP to issue the invoices corresponding to the costs detailed in the budget (ANNEX_1), the SPONSOR/CRO must inform FIBHULP in writing of the total amount to be invoiced, detailing the breakdown of the visits and procedures that have been carried out. To do so, he/she shall send an e-mail to xxxxxxxxxxxxxxx@xxxxxx.xx (**) If it is necessary to include an order or purchase order number in the invoices, this must be indicated, along with the procedure for the FIBHULP to request it Payments to the FIBHULP will be made by bank transfer, with charges payable by the sender, to: HOLDER Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP) TAX ID CODE ESG83727057 BANK La Caixa Xx. xx xx Xxxxxxxxxxx Xxxxx xx Xxxxxxxxx, 00 28037 Madrid IBAN XX00 0000 0000 0000 0000 2143 SWIFT CAIXE SBB Payments made by the SPONSOR/CRO (choose as appropriate) to the FOUNDATION will be full settlements for the former, with the FIBHULP being responsible for payment the amounts that, as appropriate, are payable to the CLINICAL TRIAL researchers. (*) Include point 5.7 only if applicable The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the CLINICAL TRIAL, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FIBHULP and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: …………………………………………………………….. …………………………………………………………….. The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the CLINICAL TRIAL and, when they have ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FIBHULP When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the CLINICAL TRIAL, the SPONSOR may assign the Equipment to the HOSPITAL, or the FIBHULP, free-of-charge, for which purpose such documents as are necessary will be formalized. In the event that additional needs for equipment are detected during performance of the CLINICAL TRIAL, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.